Elective cesarean delivery plus short-course lamivudine and zidovudine for the prevention of mother-to-child transmission of human immunodeficiency virus type 1

Panburana, Panyu; Sirinavin, Sayomporn; Phuapradit, Winit; Vibhagool, Asda; Chantratita, Wasun

doi:10.1016/j.ajog.2003.09.034

Search citation statements

Order By: Relevance

Paper Sections

Select...

Caesarean Sections and Postpartum Morbidity1

Mother-to-child Transmission Of Hiv1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2005

2014

Publication Types

Select...

Article4

Other3

Relationship

Self Cite0

Independent7

Authors

Journals

Cited by 13 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A Thai study [17] added an elective Caesarean section to a PMTCT ARV regimen of zidovudine and lamivudine from 34 weeks and to the newborn. Results were an infection rate of 4.3%.…”

Section: Caesarean Sections and Postpartum Morbiditymentioning

confidence: 99%

HIV in pregnancy

Moodley

Wennberg

2005

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

“…A Thai study [17] added an elective Caesarean section to a PMTCT ARV regimen of zidovudine and lamivudine from 34 weeks and to the newborn. Results were an infection rate of 4.3%.…”

Section: Caesarean Sections and Postpartum Morbiditymentioning

confidence: 99%

HIV in pregnancy

Moodley

Wennberg

2005

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

“…The optimal use of antenatal HAART has produced significant reductions in the incidence of MTCT, with rates falling from 25% to 1-2%. In addition, elective cesarean section and feeding of formula rather than breast milk can further reduce the rates to <1%, although complete elimination of MTCT has not been achieved [45,46].…”

Section: Mother-to-child Transmission Of Hivmentioning

confidence: 99%

Developments in Antiviral Drug Design, Discovery and Development in 2004

Meanwell

Belema²,

Carini³

et al. 2005

CDTID

View full text Add to dashboard Cite

This article summarizes key aspects of progress made during 2004 toward the design, discovery and development of antiviral agents for clinical use. Important developments in the identification, characterization and clinical utility of inhibitors of human immunodeficiency virus; the hepatitis viruses, hepatitis B, hepatitis C; the herpes family of viruses, herpes simplex viruses 1 and 2, varicella zoster virus, Epstein-Barr virus and human cytomegalovirus; the respiratory viruses, influenza, respiratory syncytial virus, human metapneumovirus, picornaviruses, measles and the severe acute respiratory syndrome coronavirus; human papilloma virus; rotavirus; Ebola virus and West Nile virus, are reviewed.

show abstract